Tardive dyskinesia (TD) is caused by prolonged use of medications that block dopamine receptors in the brain, most commonly antipsychotic drugs. At least 20% of people taking older, first-generation antipsychotics develop the condition, which produces involuntary, repetitive movements of the face, tongue, jaw, and sometimes the limbs or trunk. The risk is lower with newer antipsychotics but never zero.
How Dopamine Blockade Changes the Brain
To understand what causes TD, it helps to know what these medications do at a cellular level. Antipsychotics work by blocking dopamine receptors, particularly a type called D2 receptors, in an area of the brain that coordinates movement. When those receptors are blocked for months or years, the brain compensates by producing more of them and making the remaining ones hypersensitive to dopamine. This process is called dopamine supersensitivity.
The result is a paradox. While the medication is still blocking many receptors, the ones that aren’t blocked overreact to even normal amounts of dopamine. This throws off the finely tuned signaling in the movement-control circuits of the brain, producing the involuntary movements characteristic of TD. It also explains a frustrating clinical reality: symptoms often get worse, not better, when the medication is reduced or stopped, because all those extra-sensitive receptors are suddenly exposed to dopamine without a blocker in the way.
Which Medications Cause It
First-Generation Antipsychotics
Older antipsychotics, sometimes called “typical” antipsychotics, carry the highest risk because they bind strongly to D2 receptors. These include haloperidol, chlorpromazine, fluphenazine, perphenazine, thioridazine, and trifluoperazine. Haloperidol in particular has been shown to trigger dyskinesia partly through an inflammatory response in the brain. Patients on these drugs develop new-onset TD at a rate of roughly 5.6 cases per 100 patient-years of exposure, meaning that for every 100 people taking them for a year, about 5 or 6 will develop TD.
Second-Generation Antipsychotics
Newer “atypical” antipsychotics bind more loosely to D2 receptors and were originally expected to carry a much lower risk. Large pooled analyses suggest they cause TD at roughly one-quarter to one-half the rate of older drugs. But the risk is real. Risperidone, aripiprazole, amisulpride, and ziprasidone have all been linked to TD. One study found a 16.4% prevalence of TD in patients treated with olanzapine. People taking both old and new antipsychotics simultaneously had the highest rate of all: about 9.6 cases per 100 patient-years. Clozapine and quetiapine carry the lowest risk among antipsychotics, though neither is risk-free.
Non-Psychiatric Medications
TD isn’t limited to psychiatric drugs. Metoclopramide, a medication commonly prescribed for nausea and gastroparesis, works by blocking the same dopamine receptors. Regulatory agencies have restricted its long-term use because of TD concerns, though newer data suggests the actual risk is quite low, around 0.1% per 1,000 patient-years, far below earlier estimates of 1% to 10%. Prochlorperazine, another anti-nausea drug that is technically an antipsychotic, has actually been linked to a higher rate of TD than metoclopramide in clinical trials.
Risk Factors That Raise Your Odds
Not everyone on these medications develops TD. Several factors influence who is most vulnerable:
- Duration of use. The longer you take a dopamine-blocking medication, the greater the cumulative risk. TD can appear after months or years of treatment.
- Age. Older adults, especially women over 55, develop TD at significantly higher rates than younger patients.
- Type of medication. First-generation antipsychotics roughly double or triple the risk compared to second-generation drugs. Higher doses increase risk further.
- Genetics. Variations in a liver enzyme called CYP2D6, which breaks down many antipsychotics, play a measurable role. Surprisingly, people whose bodies metabolize these drugs faster (not slower) face higher risk. Each step up in metabolic activity increases the odds of TD roughly fourfold, likely because faster metabolism produces more active byproducts that are themselves toxic to movement circuits. Variations in dopamine and serotonin receptor genes also contribute.
- Other health conditions. Diabetes, mood disorders, and substance use have all been associated with higher TD rates.
How It’s Detected
Because TD can develop gradually, current guidelines recommend regular screening using a standardized tool called the Abnormal Involuntary Movement Scale (AIMS). This is a brief physical exam where a clinician watches for involuntary movements of the face, mouth, tongue, and extremities, often asking you to perform simple tasks like extending your arms. Updated 2020 guidelines from the American Psychiatric Association recommend AIMS screening every 6 months for people at high risk and every 12 months for others. Ideally, a baseline exam is done before starting any antipsychotic, so any new movements can be identified early.
Can It Be Reversed?
This is the question most people dread, and the honest answer is sobering. TD is difficult to reverse once established. Long-term studies report remission rates that vary widely, from 0% to 73%, but most find that fewer than 25% of people see their symptoms fully resolve. In one retrospective analysis of 106 patients who stopped taking the medication that caused their TD, the spontaneous remission rate was just 2%. With targeted treatment, the overall remission rate in that group reached only 13%.
The brain changes underlying TD, particularly the receptor upregulation and supersensitivity, can become self-sustaining over time. Early detection matters enormously. The shorter the duration of TD symptoms before intervention, the better the chances of improvement. This is one reason routine AIMS screening exists: catching subtle lip-smacking, tongue movements, or finger twitching early gives you and your prescriber more options before the changes become entrenched.
Why Stopping the Medication Isn’t Simple
A natural reaction to learning that a medication is causing involuntary movements is wanting to stop it immediately. But abruptly discontinuing antipsychotics can be dangerous for multiple reasons. The underlying psychiatric condition may return, sometimes severely. And because of the dopamine supersensitivity described above, TD symptoms often temporarily worsen when the drug is withdrawn, a phenomenon sometimes called “withdrawal dyskinesia.” In some cases, this worsening becomes permanent.
Any changes to antipsychotic medication need to be gradual and carefully monitored. For many people, the psychiatric condition being treated is serious enough that stopping the antipsychotic entirely isn’t feasible. In those cases, switching to a lower-risk antipsychotic like clozapine or quetiapine, or adding a medication specifically approved to treat TD symptoms, may be the more realistic path forward.